Ovid Therapeutics Inc. (OVID) Financial Statements (2026 and earlier)

Company Profile

Business Address 441 NINTH AVENUE, 14TH FLOOR
NEW YORK, NY 10001
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:90,44753,075105,833129,001187,79872,034
Cash and cash equivalent13,15326,30127,04244,868187,79872,034
Short-term investments56,48226,77478,79284,134  
Other undisclosed cash, cash equivalents, and short-term investments20,812     
Other undisclosed current assets(16,079)2,8653,7642,3792,6822,809
Total current assets:74,36855,940109,598131,381190,47974,843
Noncurrent Assets
Operating lease, right-of-use asset11,61012,79713,89414,923  
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization2524337691,148243136
Long-term investments and receivables20,81220,97417,6265,6231,632 
Long-term investments20,81220,97417,6265,6231,632 
Intangible asset, including goodwill, after accumulated amortization  100183222164 
Intangible asset, excluding goodwill, after accumulated amortization  100183222164 
Prepaid expense      477
Other noncurrent assets  92210261164319
Other undisclosed noncurrent assets43,8921,8311,7481,7091,863151
Total noncurrent assets:76,56636,22734,42923,8854,0661,082
TOTAL ASSETS:150,93492,167144,027155,266194,54575,926
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,8559,18510,2286,45814,79817,479
Accounts payable1,9563,1913,7031,9537,1275,446
Accrued liabilities4,8995,9946,5254,5057,67112,033
Deferred revenue      2,213
Due to related parties✕✕✕✕  2,371
Other undisclosed current liabilities1,4331,3371,246534  
Total current liabilities:8,28810,52211,4746,99214,79822,063
Noncurrent Liabilities
Liabilities, other than long-term debt11,98613,41914,75616,002 10,231
Deferred revenue      10,170
Due to related parties✕✕✕✕  61
Operating lease, liability11,98613,41914,75616,002  
Other undisclosed noncurrent liabilities   30,000   
Total noncurrent liabilities:11,98613,41944,75616,002 10,231
Total liabilities:20,27423,94156,23022,99314,79832,294
Equity
Equity, attributable to parent130,66068,22687,797132,273179,74643,632
Preferred stock   0000
Common stock1307171707066
Additional paid in capital452,445372,489365,591357,771351,034337,758
Accumulated other comprehensive income (loss)(202)(35)1(42)  
Accumulated deficit(321,713)(304,299)(277,866)(225,527)(171,358)(294,192)
Total equity:130,66068,22687,797132,273179,74643,632
TOTAL LIABILITIES AND EQUITY:150,93492,167144,027155,266194,54575,926

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues7,2525663921,503208,38312,617
Cost of revenue
(Cost of Product and Service Sold)		(273)(613)    
Gross profit:6,979(47)3921,503208,38312,617
Operating expenses(49,691)(62,451)(59,673)(57,051)(84,174)(94,048)
Other undisclosed operating income (loss)273613(0)   
Operating income (loss):(42,439)(61,885)(59,281)(55,548)124,209(81,431)
Nonoperating income
(Other Nonoperating income)		25,02635,4526,9431,379  
Income (loss) from continuing operations before equity method investments, income taxes:(17,413)(26,433)(52,339)(54,169)124,209(81,431)
Other undisclosed loss from continuing operations before income taxes(1)   (46) 
Income (loss) from continuing operations before income taxes:(17,414)(26,433)(52,339)(54,169)124,163(81,431)
Income tax expense     (1,329) 
Income (loss) from continuing operations:(17,414)(26,433)(52,339)(54,169)122,835(81,431)
Income (loss) before gain (loss) on sale of properties:✕✕✕✕✕122,835(81,431)
Net income (loss):(17,414)(26,433)(52,339)(54,169)122,835(81,431)
Other undisclosed net income attributable to parent      395
Net income (loss) attributable to parent:(17,414)(26,433)(52,339)(54,169)122,835(81,036)
Undistributed earnings (loss) allocated to participating securities, basic     (2,997) 
Other undisclosed net income available to common stockholders, basic     2 
Net income (loss) available to common stockholders, basic:(17,414)(26,433)(52,339)(54,169)119,839(81,036)
Other undisclosed net income available to common stockholders, diluted273458    
Net income (loss) available to common stockholders, diluted:(17,141)(25,975)(52,339)(54,169)119,839(81,036)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income (loss):(17,414)(26,433)(52,339)(54,169)122,835(81,431)
Other comprehensive loss      (2)
Comprehensive income (loss):(17,414)(26,433)(52,339)(54,169)122,835(81,433)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(167)(35)1(42) 395
Comprehensive income (loss), net of tax, attributable to parent:(17,581)(26,468)(52,338)(54,211)122,835(81,038)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: